Avian Influenza Epidemic to Drive the China Avian Influenza Vaccine Market 2014-2018: MarketResearchReports.biz

Share Article

Marketresearchreports.biz has announced the addition of a report titled “Research Report On China Avian Influenza Vaccine Industry 2014-2018” report to their offering.

This market research report on the China avian influenza vaccine industry provides a comprehensive overview of the market structure and dynamics of the avian influenza vaccine industry in China. The introductory part of the report discusses the current conditions prevailing in the global and China avian influenza vaccine market. Furthermore, it explains the definition and significance of the avian influenza vaccine. The report also throws light on the epidemic situation of avian influenza, which drives the avian influenza vaccine market all across the globe. The research study explains the factors responsible for the frequency of avian influenza in China as well as the rest of the world.

View Full Report at http://www.marketresearchreports.biz/analysis/225104

The report offers useful insights into the factors that propel the China avian influenza vaccine market. Most importantly, the report throws light on the policies implemented in the China market for animal vaccines, which covers aspects like organization structure, legislation of animal epidemic prevention, and the appropriation budget of epidemic prevention. Other policy measures with regard to immunization against the highly pathogenic avian influenza, including the scope of compulsory immunization for poultry, have also been discussed in this research report. For better understanding of the China avian influenza vaccine market, the research study throws light on its historical background by discussing the breeding status of chicken and ducks.

Download Detail Report With COmplete TOC at http://www.marketresearchreports.biz/sample/sample/225104

This market research report on the China avian influenza vaccine market describes the demand and supply determinants prevailing in this market. It provides a detailed analysis of the supply patterns and the factors that have a significant impact on them. Similarly, the report analyzes the demand trends and also explores the factors affecting the overall demand in the China avian influenza vaccine market. An ongoing trend prevailing in this market with regard to the status of free avian influenza vaccines as provided by the government has also been discussed in the report. As a result, the research study also analyzes the current problems in the China avian influenza vaccine market and their solutions.

With the help of charts, tables, figures, statistical data, and facts, this research study on the China avian influenza vaccine market provides a strong foundation for future market predictions. Also, the report throws light on the demand for avian influenza vaccines from some of the local administrations in China. The research study provides a comprehensive analysis of the competitive landscape in the China avian influenza vaccine market by describing the individual company profiles of the various avian influenza vaccine manufacturers operating in the market. The report throws light on crucial aspects such as the companies’ SWOT analysis, revenue structures, business strategies, demand drivers and inhibitors, financial positions, and scope for further growth.

Explore All Influenza Vaccine Market Research Reports at http://www.marketresearchreports.biz/tag/Influenza-Vaccine

Shandong Sinder Technology Co., Ltd., Qingdao Yebio Bioengineering Co., Ltd., Harbin Weike Biotechnology Development Company, Guangdong Winsun Pharmaceutical Co., Ltd., and Zhaoqing Dahuanong Animal Health Products Co., Ltd., are some of the prominent manufacturers in the China avian influenza vaccine market.

Related Reports

China Pharmaceutical Excipients Industry Report, 2014-2017

View Full Report at http://www.marketresearchreports.biz/analysis/232334

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are also contained in pharmaceutical preparations after reasonable safety assessment. China has launched more than 500 types of pharmaceutical excipients, far less than 1,500 types of the United States and 3,000 types of Europe. By market size, gelatin capsules, sucrose, starch, film-coated powder, 1,2-propylene glycol, polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), microcrystalline cellulose, hydroxypropyl cellulose (HPC) and lactose rank as the top 10 pharmaceutical excipients in China.

Download Detail Report at http://www.marketresearchreports.biz/sample/sample/232334

Among them, the traditional pharmaceutical excipients --gelatin capsules are involved with adequate supply and large export volume. In H1 2014, China’s gelatin capsule export volume amounted to 1,427.5 tons and the export value hit USD32.408 million. However, China still relies on the import of film-coated powder, polyvinylpyrrolidone (PVP) and other new-type high-end pharmaceutical excipients.

China Recombinant Protein Drug Industry Report, 2014-2017

View Full Report at http://www.marketresearchreports.biz/analysis/232274

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein drugs available in Chinese sample hospitals grew at a CAGR of 19.1%, and it is projected that China will see its actual demand for recombinant protein drugs exceed RMB40 billion in 2014.

Download Detail Report at http://www.marketresearchreports.biz/sample/sample/232274

The start of recombinant protein drugs in China is not late and common drugs are diversified in variety, for example, recombinant human erythropoietin (rhEPO), recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human interferon (rhIFN) have gained market approval in the 1990s. Moreover, in 2013, domestic rhG-CSF, rhEPO andrecombinant human growth hormone (rhGH) with price advantage took a respective share of 82.1%, 88.5% and 90.2% in Chinese sample hospitals, and recombinant human interleukin-2/11(rhIL-2/11) was fully localized.

About MarketResearchReports.biz

Marketresearchreports.biz is the most comprehensive collection of market research reports, supporting clients’ market intelligence needs with over 100,000 market research reports, company profiles, data books, and regional market profits in its repository. We also offer consulting support for custom market research needs.

Our document database is updated by the hour, which means that our customers always have access to fresh data spanning over 300 industries. From Fortune 500 companies to SMEs, Marketresearchreports.biz has built a veritable reputation for fulfilling the most exacting market research needs.

Contact:

Atil Chuadhari
State Tower
90 State Street,
Suite 700, Albany
NY 12207, United States
Toll Free: 866-997-4948
Email: sales(at)marketresearchreports(dot)biz

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michell Thoras

Sheela AK
Follow us on
Visit website